Article Information
History
- October 5, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Tom Sumner1,2,3,*,
- Rebecca A. Clark1,2,3,4,
- Christinah Mukandavire1,2,3,
- Allison Portnoy5,6,
- Chathika K. Weerasuriya1,2,3,
- Roel Bakker1,2,3,7,
- Danny Scarponi1,2,3,
- Mark Hatherill8,
- Nicolas A. Menzies6,9 and
- Richard G. White1,2,3
- 1TB Modelling Group and TB Centre, London School of Hygiene and Tropical Medicine
- 2Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine
- 3Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine
- 4Vaccine Centre, London School of Hygiene and Tropical Medicine
- 5Department of Global Health, Boston University School of Public Health, Boston, USA
- 6Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, USA
- 7KNCV Tuberculosis Foundation
- 8South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town
- 9Department of Global Health and Population, Harvard T.H. Chan School of Public Health
- ↵*Corresponding author; email: tom.sumner{at}lshtm.ac.uk
Posted October 05, 2023.
Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: estimates for South Africa
